Porównanie skuteczności testu drugiej genereacji Beckman Coulter IVD oraz testu pierwszej generacji AnshLabs ELISA w ocenie surowiczych stężeń hormonu AMH u pacjentek poddawanych leczeniu za pomocą zapłodnienia pozaustrojowego in vitro by Lukaszuk, Krzysztof et al.
©  P o l s k i e  T o w a r z y s t w o  G i n e k o l o g i c z n e Nr 9/2014778
    
Ginekol Pol. 2014, 85, 778-783 
P R A C E  O R Y G I N A L N E
  niepłodność
Comparison of the second-generation Beckman 
Coulter IVD and first-generation AnshLabs 
ELISA assays for anti-Müllerian hormone in 
patients undergoing IVF treatment 
Porównanie skuteczności testu drugiej genereacji Beckman Coulter IVD 
oraz testu pierwszej generacji AnshLabs ELISA w ocenie surowiczych 
stężeń hormonu AMH u pacjentek poddawanych leczeniu za pomocą 
zapłodnienia pozaustrojowego in vitro
 
Krzysztof	Lukaszuk1,2,3,	Waldemar	Kuczynski4,5,	Michal	Kunicki3,	Beata	Ludwikowska1, 
Joanna	Liss1,	Iwona	Malinowska1,	Aron	Lukaszuk1, Alicja Bednarowska3,	Agnieszka	Kuczynska5,6, 
Pawel Kuc5,7,	Ewa	Pastuszek1,2 
1 INVICTA Fertility and Reproductive Centre, Gdansk, Poland
2 Department of Nursing, Medical University, Gdansk, Poland
3 INVICTA Fertility and Reproductive Centre, Warsaw, Poland
4 Department of Gynecology, Medical University of Białystok, Bialystok, Poland
5 Centre for Reproductive Medicine KRIOBANK, Bialystok, Poland
6 Department of Gynecological Endocrinology, Medical University of Bialystok, Bialystok, Poland
7 Department of Perinatology, Medical University of Bialystok, Bialystok, Poland 
 Abstract    
Objectives: Ovarian reserve is the main factor influencing the efficacy of infertility treatment. Currently, the anti-
Müllerian hormone is the main indicator of the ovarian reserve and has a wide spectrum of clinical importance. It 
achieved a high clinical value right after the introduction of the first commercial AMH assays in 2005. Lack further 
research and development of the tests and monopoly on their production have led to a significant reduction of their 
quality, resulting in lowered veracity and usefulness. Therefore, we searched for an alternative to the Beckman 
Coulter assay. The objective of the study was to draw a comparison between the commonly used second-generation 
assay by Beckman Coulter and the ultra-sensitive first-generation assay by AnshLabs. 
Materials and methods: Serum samples (n=520) were collected from female patients undergoing routine AMH 
evaluation before entering an IVF program. We chose samples of patients with the lowest correlation between the 
AMH serum level and response to stimulation. The AMH serum levels of the patients were examined using two AMH 
tests, the second-generation assay by Beckman Coulter and the first-generation assay by AnshLabs. Precision and 
accuracy of both methods were determined and the results of AMH serum levels of 130 patients were correlated 
with the number of: antral follicles (AFC), follicles after stimulation, and the obtained cumulus cells.
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Introduction
Oocyte	quality	depends	on	maternal	age	and	ovarian	reserve	
but	it	shows	no	direct	correlation.	Precise	assessment	of	a	woman’s	
ovarian	 reserve	 has	 constituted	 the	 main	 problem	 in	 medical	
treatment	of	 infertility	 for	many	years.	At	present,	 a	variety	of	
diagnostic	tests	are	used	in	Poland	to	evaluate	the	ovarian	reserve.	
The	 most	 common	 are:	 serum	 levels	 of	 follicle-stimulating	
hormone	(FSH),	estradiol,	inhibin	B	and	anti-Müllerian	hormone	
(AMH)	 in	 the	 early	 follicular	 phase,	 as	 well	 as	 antral	 follicle	
count	(AFC)	[1].	Nowadays,	AMH	level	is	considered	to	be	the	
best	marker	of	the	ovarian	reserve.	The	anti-Müllerian	hormone,	
also	known	as	the	Müller	inhibiting	substance	(MIS),	is	a	dimeric	
glycoprotein	 belonging	 to	 the	 transforming	 growth	 factor-β	
(TGF-β)	family	[1-3].
The	AMH	 serum	 level	 reflects	 the	 pool	 of	 small	 ovarian	
follicles	–	when	 the	amount	of	growing	follicles	decreases,	 the	
AMH	serum	level	also	falls.	[4].	Its	expression	is	the	highest	in	
the	antral	and	pre-antral	follicles.	Through	its	paracrine	activity,	
AMH	inhibits	both,	growth	stimulated	by	FSH	and	development	
of	 other	 primary	 follicles,	 while	 ensuring	 the	 selection	 of	 the	
dominant	follicle	[5-8].
Constant	level	of	AMH	during	the	menstrual	cycle	makes	it	
a	unique	endocrinal	parameter	in	measuring	female	gonad	func-
tion,	allowing	to	estimate	patient	fertility	rate	and	to	approximate	
the	 time	 of	 conception	 [4,	 9,	 10].	 Even	 undetectable	 levels	 of	
AMH	do	not	exclude	the	possibility	of	conceiving	[11,	12].
Currently,	 evaluation	 of	 AMH	 is	 important	 in	 assisted-
reproduction	methods,	where	the	hormone	level	is	used	to	predict	
Results: Both, precision and accuracy of the compared methods were highly satisfactory. The coefficients of varia-
tion obtained in the study conducted on two different levels of control material were lower than 12% and the load did 
not exceed 9%. The study proved that both of the methods yielded comparable results. The coefficient of variation 
between the first-generation and the second-generation AMH assays was 0.871. 
Conclusion: Both methods might be applied in the evaluation of the ovarian reserve. The first- and second-gen-
eration assays show comparable correlation with the clinical effects of stimulation, however, it seems that first-gen-
eration assays are a better alternative to the unstable second-generation kits. The results from the first-generation 
assays are distributed on a wider range, which facilitates clinical interpretation. 
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 Streszczenie
Cel pracy: Ocena rezerwy jajnikowej jest głównym czynnikiem wpływającym na skuteczność leczenia niepłodno-
ści. Obecnie jednym z głównych wykładników rezerwy jajnikowej jest hormon antymüllerowski (AMH), który zyskał 
swoje szczególne znaczenie w 2005 roku tuż po prezentacji pierwszego komercyjnego zestawu laboratoryjnego 
do jego oznaczania w surowicy. Brak rozwoju badań nad produktem i monopolizacja jego produkcji doprowadziły 
do znacznego obniżenia jakości testu, a tym samym znacznie obniżając wiarygodność wyników i ich przydatność. 
Dlatego też, poszukujemy alternatywy dla testu Beckmana Coultera. 
Celem pracy było porównanie skuteczności testu pierwszej generacji AnshLabs z  testem drugiej genereacji 
Beckman Coulter w ocenie surowiczych stężeń hormonu antymüllerowskiego u pacjentów w trakcie leczenia za 
pomocą zapłodnienia pozaustrojowego in vitro. 
Materiał i  metodyka: Próbki surowicy krwi do oznaczeń AMH (n=520) zostały pobrane od pacjentek przed 
rozpoczęciem kontrolowanej stymulacji jajników w programie zapłodnienia poza ustrojowego in vitro. Celem wiary-
godniejszej analizy, do porównania wybrane zostały jedynie próbki surowicy krwi od pacjentek z niską zależnością 
między poziomem AMH a odpowiedzią na stymulację. Ocena surowiczych stężeń AMH dla testu Beckman Coulter 
oraz testu AnshLabs wykonana została metodą dwukrotnych powtórzeń.
Precyzja i  dokładność obu metod została wyznaczona, a  wyniki badań wykazały dodatnią korelację pomiędzy 
surowiczymi stężeniami AMH w surowicy krwi 130 pacjentek a liczbą pęcherzyków antralnych w jajnikach, ilością 
pęcherzyków po stymulacji oraz liczbą uzyskanych kumulusów.
Wyniki: Zarówno precyzja jak i dokładność obu zastosowanych metod była zadowalająca. Współczynniki zmien-
ności uzyskane w badaniu przeprowadzone na dwóch różnych poziomach grupy kontrolnej były niższe niż 12%, 
a obciążenie nie przekraczało 9%. Badania wykazały, że obie metody dały podobne wyniki, a współczynnik zmien-
ności między testem pierwszej generacji i testem drugiej generacji był na poziomie 0.871. 
Wnioski: Obie metody mogą być stosowane w ocenie rezerwy jajnikowej. Zestawy obu generacji wykazują po-
równywalną korelację z klinicznymi efektami stymulacji, jednak zestawy pierwszej generacji wydają się być lepszą 
alternatywą wobec niestabilnych zestawów drugiej generacji. Dzięki szerszemu zakresowi wyników w przypadku 
użycia testów pierwszej generacji łatwiejsza jest ich interpretacja kliniczna. 
 Słowa kluczowe: hormon anti-müllerowski / testy pierwszej generacji /  
       / testy drugiej generacji /
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patient	 response	 to	 stimulation	 [13-16].	However,	AMH	might	
be	 used	 for	 many	 other	 reasons,	 for	 example	 as	 a	 diagnostic	
criterion	for	the	differentiation	of	secondary	amenorrhea.	AMH	
concentration	 significantly	 increases	 in	women	with	 polycystic	
ovary	syndrome	(PCOS)	and	is	significantly	reduced	in	premature	
expiration	of	the	ovarian	function	(POF),	but	remains	unchanged	
in	 hypogonadism	 and	 hyperprolactinemia	 [9,17].	 AMH	 might	
also	 be	 used	 to	 assess	 the	 level	 of	 damage	 caused	 by	 ovarian	
surgery	 or	 chemotherapy	 [18,19].	 Furthermore,	 serum	 AMH	
concentration	might	also	predict	an	estimated	time	to	menopause	
in	a	patient	[20-22].
AMH	 serum	 level	 may	 be	 determined	 using	 a	 variety	
of	 assays:	 the	 original	 research	 assays,	 the	 first-generation	
Diagnostic	Systems	Laboratories	(DSL)	and	Immunotech	assays,	
or	the	second-generation	Beckman	Coulter	assay,	which	combines	
the	 cross-species	 DSL	 antibodies	 according	 to	 Immunotech	
standards.	Also,	 the	 new,	 fully	 automated	AMH	 assay	 will	 be	
released	soon	by	several	companies.	AMH	molecules	are	found	
in	 the	 serum	 as	 partly	 digested	 dimers.	 Due	 to	 the	 molecular	
structure	 of	 AMH,	 the	 assays	 usually	 use	 immunochemical	
methods	with	different	detection	systems.	The	European	market	
of	 diagnostics	 tools	 offers	 several	AMH	 testing	 sets	 using	 the	
enzyme-linked	immunosorbent	assay	(ELISA)	technique,	as	well	
as	 the	 second-generation	 assay	 by	 Beckman	 Coulter,	 which	 is	
currently	the	most	widely	used.
Rapid	 commercialization	of	 scientific	methods	has	 created	
standardization	gaps	in	various	products	-	in	this	case	the	AMH	
assays	–	which	are	difficult	to	bridge.	Large	companies	take	over	
smaller	ones,	what	destroys	competitiveness	and	often	 leads	 to	
reduced	product	quality.	Evolution	of	the	tests	and	monopoly	on	
their	production	have	 led	 to	 	 reduced	quality	of	 sets,	 including	
reliability	 and	 usefulness	 of	AMH	 assays.	 Variety	 of	 patterns,	
flexible	selection	of	antibodies	added	 to	 the	 reagents,	and	 their	
susceptibility	 to	 interfering	 factors,	 are	 the	 reasons	 why	 sets	
differ	 in	 sensitivity,	 specificity,	 linearity,	 range,	 precision	 and	
accuracy.	Ultimately,	they	make	the	comparison	of	the	obtained	
results	impossible.	Reliable	results	of	AMH	levels	are	of	utmost	
importance	 as	 incorrect	 results	 might	 lead	 to	 wrong	 decisions	
concerning	further	diagnosis	and	treatment	strategies.	The	aim	of	
our	study	was	to	compare	the	AMH	levels	measured	with	the	use	
of	two	different	assays	(the	second-generation	Beckman	Coulter	
set	and	the	first-generation	ultra-sensitive	set	by	AnshLabs).
Material and methods
The	 analyzed	material	 included	 520	 blood	 serum	 samples	
from	patients	undergoing	 routine	AMH	 tests	before	 starting	 an	
IVF	Program	(BC	II	IVD),	between	October	2012	and	February	
2013.	We	selected	130	serum	samples	of	patients	with	the	lowest	
and	 the	highest	 ratio	of	 the	number	of	 antral	 follicles	 to	AMH	
for	comparison.	The	average	ratio	was	9.2±2.28.	The	 inclusion	
criterion	was	the	location	of	the	ratio	in	the	12.5%		of	the	results	
in	both	extremes.	Then,	the	determination	of	AMH	serum	levels	
from	 the	same	material	was	made	with	 the	first-generation	 test	
by	AnshLabs.	Correlations	between	AMH	levels	and	the	number	
of:	 antral	 follicles,	 follicles	 after	 stimulation,	 and	 the	 obtained	
cumulus	cells	were	also	examined.	
Blood	sampling	was	performed	between	day	1	and	5	of	the	
cycle.	The	blood	was	collected	aseptically	into	tubes	with	clotting	
activator,	using	a	vacuum	blood	collection	 system	 (Vacutainer;	
Becton	Dickinson).	After	clotting	was	complete,	blood	samples	
were	centrifuged	(10	min,	1500	x	g)	to	obtain	sera.	The	obtained	
sera	were	frozen	at	-80°C	until	analysis.	AMH	was	measured	by	
ELISA	-	firstly	by	sets	of	the	second-generation	of	AMH	Gen	II	
ELISA	Beckman	Coulter	(Beckman	Coulter	Inc.,	Brea,	CA	USA)	
and	 then	by	 sets	 of	 the	first-generation	of	 ultrasensitive	AMH/
MIS	ELISA	by	AnshLabs.	Detection	limits	of	the	sets	were	0.08	
and	0.02	ng/ml,	respectively	(Table	I).
In	 the	 first	 stage	 of	 the	 study,	 precision	 of	 the	AMH	 tests	
was	 evaluated	 for	 two	 different	 control	 sera,	 supplied	 by	 the	
manufacturers	 (Controls	 1	 and	 2	 for	 Beckman	 Coulter,	 and	
CTR-I	and	-II	for	AnshLabs).
The	AnshLabs	 control	 material	 was	 supplied	 lyophilized.	
Determination	of	AMH	in	the	above-mentioned	control	material	
was	 carried	 out	 according	 to	 the	 Clinical	 and	 Laboratory	
Standards	 Institute	 protocol	 (CLSI).	 The	 tests	 were	 performed	
by	 determining	 the	 level	 of	AMH	 twice	 in	 one	 day,	 at	 2-hour	
intervals	and	in	two	samples.	The	total	number	of	measurements	
for	one	of	the	analyzed	levels	of	control	material	was	20.	In	the	
assessment	of	the	accuracy	of	the	results,	we	used	the	degree	of	
agreement	 between	 the	 average	 value	 obtained	 from	 the	 series	
of	control	 tests,	and	the	predicted	value	for	a	particular	control	
material	level	declared	by	the	manufacturer	[23].
Both	 sets	 of	 AMH	 Gen	 II	 ELISA	 Beckman	 Coulter	 and	
Gen	 I	AnshLabs	 tests	are	“sandwich”	 type	 immunoassays.	The	
calibrators,	controls	and	samples	are	incubated	in	the	wells	that	
have	 been	 coated	 with	 anti-AMH	 antibody.	 After	 incubation	
and	washing,	 an	anti-AMH	labelled	by	biotin	 is	 added	 to	each	
well.	 After	 the	 second	 stage	 of	 the	 incubation	 and	 washing,	
horseradish	 peroxidase	 (HRP)-conjugated	 with	 streptavidin	
is	 added	 to	 the	 wells.	 After	 another	 incubation	 and	 washing,	
tetramethylbenzidine	 (TMB)	 is	 added	 to	 the	wells.	 In	 the	final	
stage	 of	 the	 test,	 a	 solution	 of	 the	 acid	 is	 added	 to	 stop	 the	
reaction.	The	level	of	binding	of	tracers	to	the	base	is	determined	
by	 the	 absorbance	measurement	 at	 dual	wavelength	 at	 450	nm	
and	 from	600	 to	630	nm.	The	measured	absorbance	 is	directly	
proportional	to	the	concentration	of	AMH	in	samples.	The	AMH	
calibrator	set	 is	used	 to	draw	a	calibration	curve	of	absorbance	
versus	concentration	of	AMH,	from	which	concentration	can	be	
calculated	from	the	calibration	curve.
In	both	cases,	the	AMH	assay	results	are	presented	in	units	
of	ng/ml.	Serum	samples	with	results	above	the	upper	measuring	
range	 for	 each	 method	 were	 diluted	 automatically	 (using	 the	
reagents	 supplied	 by	 the	 manufacturers	 of	 the	 assays)	 and	 re-
analyzed.	Measuring	ranges	for	reagent	kits	used,	their	functional	
sensitivity	and	analytical	sensitivity	are	presented	in	Table	I.
MedCalc	 12.1.4.0	 and	Statistica	 ver.	 10	 (Tulsa	OK,	USA)	
were	 used	 to	 evaluate	 the	 results.	 Pearson	 correlation	 analysis	
and	 Passing-Bablok	 regression	 equation	were	 used	 to	 estimate	
the	 relationship	 between	 the	 obtained	 results	 with	 different	
analyses.	Student's	t-test	for	dependent	pairs	was	used	to	assess	
the	 significance	 of	 differences.	Bland	 and	Altman	graphs	were	
used	to	visualize	the	data	scatter	[24].
Results
Results	 of	precision	 and	 accuracy	of	 each	AMH	assay	 are	
shown	 in	 Table	 II.	 The	 obtained	 coefficients	 of	 variation	 for	
compared	 sets	 of	 analytical	 and	 evaluated	AMH	 values	 were	
satisfactory.	In	each	case,	 the	analyzed	CV	value	was	less	 than	
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12%.	For	both	methods	compared,	correctness	was	satisfactory	
-	 in	all	of	 the	analyzed	cases	 the	load	did	not	exceed	the	value	
of	9%.
Correctness	 of	 AMH	 results	 obtained	 by	 AMH	 Gen	 II	
ELISA	Beckman	Coulter	 assay	was	 higher	 than	 by	AMH/MIS	
ELISA	 AnshLabs	 assay.	 Comparative	 results	 of	 both	 AMH	
tests,	performed	on	the	same	material	and	at	the	same	time,	are	
summarized	in	Table	III.
Average	 values	 for	 specified	 levels	 of	 AMH	 were	 not	
comparable	 with	 each	 other:	 they	 were	 lower	 for	 Beckman	
Coulter	assays	than	for	AnshLabs	assays.	Student's	t-test	showed	
no	statistically	significant	differences	between	the	averages	only	
in	 the	 group	 of	 women	 aged	 38-39	 years.	 Pearson	 correlation	
coefficient	 calculated	 for	 the	 relationship	between	AMH	 levels	
obtained	by	the	compared	analytical	methods	was	high	(0.871),	
and	 the	 Passing-Bablok	 regression	 equation	 was	 as	 follows:	
Table I. Characteristics of the compared methods.
Measuring range (ng/ml) Analytical sensitivity (ng/ml)
AMH Gen II ELISA Beckman Coulter 0.08 – 22.5 0.08
AMH/MIS ELISA AnshLabs 0.02 - 10.7 0.02
ELISA – enzyme-linked immunosorbent assay, AMH – Anti-Müllerian Hormone
Table II.  The results of the precision and accuracy of both AMH assays.
Control
sample
Nominal
value
Precision Correctness
average min max SD CV% bias bias %
AMH Gen II ELISA Beckman Coulter
Control 1 2.9 2.86 2.51 3.11 0.22 7.7 -0.01 -1.4
Control 2 8.2 8.47 7.44 9.65 0.58 6.8 0.03 3.3
AMH/MIS ELISA AnshLabs
CTR-I 1.2 1.09 0.84 1.3 0.12 11.1 -0.09 -9.0
CTR-II 3.7 3.5 2.89 4.0 0.41 11.7 -0.05 -5.3
CV – coefficient of variation, AMH – Anti-Müllerian Hormone, SD – standard deviation
Table III. The comparison of AMH values in both tests.
<35 years 35-37 years 38-39 years >39 years
AMH Beckman 1.95 ± 2.00 (69) 1.42 ± 1.50  (23) 1.52 ±  2.13 (17) 1.08 ± 0.98 (21)
AMH AnshLabs 3.25 ± 3.02 (69) 2.93 ± 3.05 (23) 1.89 ± 1.57 (17) 2.27 ± 2.59 (21)
p-valuea < 0.0001 0.0004 0.2807 0.0059
Data are presented as means ± standard deviation (SD) (n- number of tested samples)
a Student’s t-test. 
Table IV. The correlation between AMH levels and the number of antral follicles (AFC), number of follicles after stimulation and number of acquired cumuluses.
Age groups AFC amount of follicles after stimulation
number of acquired 
cumuluses
<35 years
AMH Beckman 0.59 -0.26 -0.33
AMH AnshLabs 0.64 -0.25 -0.34
35-37 years
AMH Beckman 0.74 -0.3 -0.42
AMH AnshLabs 0.79 -0.33 -0.44
38-39 years
AMH Beckman 0.64 -0.03 -0.39
AMH AnshLabs 0.52 0.22 -0.05
>39 years
AMH Beckman 0.68 0.23 0.04
AMH AnshLabs 0.76 0.39 0.18
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AMH
(AMH/MIS	ELISA	AnshLabs)
	=	0.6168	+	1.3512	·	AMH
(Gen	II	ELISA	Beckman	
Coulter)
	(Figure	1).	In	both	cases,	a	linear	relationship	was	presented.	
Dispersion	of	the	results	obtained	with	both	methods	is	presented	
in	the	Bland-Altman	graphs	(Figure	2).
Correlation	between	AMH	levels	and	 the	number	of	antral	
follicles,	follicles	obtained	after	stimulation	and	acquired	cumulus	
cells	was	also	examined	(combination	of	the	results	–	Table	IV).	
The	first-generation	assay	showed	a	slightly	higher	coefficient	of	
correlation	with	 clinical	 status	 of	 the	 patients	 than	 the	 second-
generation	assay.
Discussion
Ensuring	 good	 quality	 of	 AMH	 evaluation	 is	 the	 basis	
of	good	 research	 in	 the	field	of	women’s	ovarian	 reserve.	This	
determination	 should	 be	 sufficiently	 sensitive,	 analytically	 and	
functionally,	 and	 the	 spectrum	 of	 the	measured	 concentrations	
should	be	relevant	to	those	that	are	most	common	in	the	patient	
population.	 Our	 findings	 demonstrated	 that	 the	 precision	 of	
both,	AMH/MIS	ELISA	by	AnshLabs	and	AMH	Gen	II	ELISA	
by	 Beckman	 Coulter	 met	 these	 requirements.	 Although	 the	
nominal	 values	 of	 AMH	 in	 control	 material	 supplied	 by	 the	
manufacturers	were	 slightly	 different	 from	 the	 assumed	 values	
(which	 is	 particularly	 evident	 in	 the	 case	 of	AnshLabs	 control	
material),	 the	 obtained	 coefficients	 of	 variation	 in	 each	 of	 the	
analyzed	cases	were	lower	than	12%.	This	allows	us	to	conclude	
that	both	methods	offer	adequate	precision	of	determination	and	
the	information	about	 the	efficacy	of	 the	determination	showed	
in	methodical	 brochures	 is	 consistent	with	 the	 results	 obtained	
in	our	study.
The	 narrower	 range	 of	AMH	 linearity	 for	 the	AMH/MIS	
ELISA	by	AnshLabs	in	comparison	with	the	AMH	Gen	II	ELISA	
by	Beckman	Coulter	is	of	little,	if	any,	practical	significance.	The	
percentage	 of	 samples	 above	 the	measuring	 range	was	 similar	
for	 both	 methods.	 The	 AMH/MIS	 ELISA	 AnshLabs	 assay	 is	
characterized	 by	 higher	 analytical	 sensitivity	 and	 functional	
sensitivity	(Table	I	–	manufacturer's	data),	so	it	is	able	to	detect	
lower	concentrations	of	AMH,	which	can	be	particularly	useful	in	
the	assessment	of	the	ovarian	reserve.
Although	correctness	of	AMH	determination	by	AMH	Gen	
II	 ELISA	 set	 from	 Beckman	 Coulter	 was	 slightly	 better	 than	
AMH/MIS	 ELISA	 set	 from	AnshLabs,	 it	 seems	 unlikely	 that	
the	 obtained	 differences	 might	 affect	 the	 interpretation	 of	 the	
acquired	 results	 in	a	 statistically	 significant	way.	Regardless	of	
the	 analytical	method,	 the	 result	 load	was	 lower	 than	9%.	The	
obtained	data	clearly	showed	that	correctness	of	the	results	was	
satisfactory	and	the	load	factor	was	much	lower	than	expected	by	
the	experts	on	laboratory	quality	management,	where	the	upper	
range	of	permissible	error	ranges	from	15	to	20%.
Comparison	 of	 AMH	 tests	 made	 in	 the	 sera	 of	 patients	
undergoing	routine	determination	of	AMH	before	IVF	programs	
also	 confirms	usefulness	of	 both	methods	 in	 terms	of	 analysis.	
Both	methods	were	 characterized	 by	 a	 linear	 relationship	with	
a	 high	 correlation	 coefficient	 (0.871).	 The	 results	 acquired	 by	
Beckman	 Coulter	 assay	were	much	 lower	 than	 those	 obtained	
by	the	AnshLabs	assay,	but	the	calculated	conversion	coefficient	
from	one	 test	 to	 another	 is	 not	 constant.	Both	 assays	 could	 be	
used	 for	 sera	which	are	not	properly	preserved.	The	 laboratory	
procedures	are	comparable	and	not	different	from	other	ELISA	
methods.	Also,	their	cost	is	comparable.
AMH	 not	 only	 has	 a	 strong	 relationship	with	 the	 number	
of	 antral	 follicles,	 but	 it	 is	 also	 the	 best	marker	 amongst	 other	
typical	 biomarkers	 correlating	 with	 AFC	 [25].	 There	 is	 an	
ongoing	debate	about	the	usefulness	of	AMH	and	AFC	in	ovarian	
response	to	stimulation	for	IVF.	The	correlations	between	AMH	
and	response	to	stimulation	vary	for	different	kits.	AFC	depends	
on	the	observers,	their	experience	and	ultrasound	machines	used.	
That	is	why	the	AMH,	after	finding	a	stable	measurement	system,	
will	be	more	comparable	for	clinicians	and	scientists.	
Our	 findings	 of	 poor	 correlation	 between	 both	 assays	 and	
the	 number	 of	 the	 received	 follicles	 and	 cumulus	 cells	 after	
stimulation	should	not	be	interpreted	as	the	assessment	of	quality	
of	AMH	assays	 in	 general,	 as	we	 selected	 the	 extremes	 of	 the	
results	for	our	analysis.	We	wanted	to	compare	both	assays	and	we	
found	similar	results.	These	results	might	lower	the	applicability	
 
Figure 1. Passing and Bablok regression analysis between AMH concentrations 
(ng/ml) obtained with AMH/MIS ELISA AnshLabs and Gen II ELISA Beckman Coulter 
assays for 130 serum samples. Linear regression analysis results were r = 0.871;  
P < 0.0001; AMH (AnshLabs) = 0.6168 + 1.3512 · AMH (Beckman Coulter).
 
Figure 2. Bland-Altman plot of the agreement between AMH/MIS ELISA AnshLabs 
and Gen II ELISA Beckman Coulter assays (solid line = mean difference; dotted lines 
= 95% CI).
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of	 AMH	 kits	 in	 predicting	 the	 success	 of	 controlled	 ovarian	
stimulation	in	IVF	treatment	.	Different	correlation	of	each	AMH	
assay	 and	 effects	 of	 stimulation	 –	 negative	 for	 younger	 and	
positive	for	older	subjects	-	are	caused	by	differences	in	patient	
population.	As	we	chose	 the	 extremes	of	 the	 results	 from	both	
sides,	we	got	high	AFC	and	AMH	for	younger	and	low	for	both,	
younger	and	older	subjects.	Low	AFC	facilitates	a	more	precise	
count	of	the	follicles,	whereas	in	case	of	high	AFC	the	precision	
is	lower,	what	can	influence	the	results.
AMH	level	is	also	significantly	correlated	with	the	number	
of	follicles	obtained	after	stimulation	and	the	number	of	oocytes	
acquired	in	 the	IVF	cycle.	Several	studies	showed	a	possibility	
of	evaluating	the	ovarian	reserve	based	on	the	AMH	serum	level,	
and	 predicting	 the	 risk	 of	 low,	 average	 or	 excessive	 ovarian	
response	 to	 stimulation	 [14,15,26].	 Also,	 some	 authors	 report	
a	 relationship	 between	AMH	 serum	 level	 and	 approximate	 the	
rate	 of	 live	 births	 [10,27].	 Identification	 of	 higher	 response	 to	
stimulation	in	a	patient	allows	for	more	effective	treatment	and	
prevention	 of	 the	 ovarian	 hyperstimulation	 syndrome	 (OHSS)	
[28-29].
Conclusions
Our	 study	 aimed	 to	 evaluate	 correlation	 between	 serum	
levels	of	AMH	determined	by	the	first	and	the	second-generation	
assays,	 and	 clinical	 parameters	 for	 ovarian	 response,	 i.e.	 the	
number of antral follicles, follicles obtained after stimulation, 
and	acquired	cumulus	cells.	Both	methods	might	be	applied	 in	
the	evaluation	of	the	ovarian	reserve	in	IVF	treatment.	The	first-
generation	 assay	 showed	 comparable	 correlation	 between	 the	
measured	serum	AMH	level	and	the	clinical	features,	therefore	it	
seems	to	be	a	good	alternative	to	the	unstable	second-generation	
assays.	The	results	from	the	first	generation	assays	are	distributed	
on	the	wider	range,	which	facilitates	clinical	interpretation.
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